Targeted genome editing in human repopulating haematopoietic stem cells

Area of Science:

• * Hematology
• * Molecular Biology
• * Gene Therapy

Background:

• * Targeted genome editing using artificial nucleases aims for site-specific transgene integration and gene correction.
• * Application in long-term repopulating hematopoietic stem cells (HSCs) has been challenging due to limited gene transfer and DNA repair.
• * Barriers include poor permissiveness to gene transfer and low homology-directed DNA repair proficiency in human HSCs.

Purpose of the Study:

• * To overcome barriers in gene targeting human HSCs.
• * To demonstrate successful site-specific integration and long-term multilineage repopulation of gene-edited HSCs.
• * To validate the therapeutic potential for X-linked severe combined immunodeficiency (SCID-X1).

Main Methods:

• * Tailored delivery platforms and optimized culture conditions were employed to enhance gene transfer and repair.
• * Stringent evidence of targeted integration was achieved through long-term multilineage repopulation assays in transplanted mice.
• * Gene editing focused on correcting the IL2RG gene in HSCs from healthy donors and SCID-X1 patients.

Main Results:

• * Successful targeted integration of corrective DNA into the IL2RG gene of human HSCs was confirmed.
• * Gene-edited HSCs demonstrated sustained normal hematopoiesis and produced functional lymphoid cells.
• * Edited lymphoid cells showed a selective growth advantage over unedited cells with disruptive IL2RG mutations.

Conclusions:

• * The study successfully overcame key barriers to gene targeting in human HSCs.
• * This strategy holds significant therapeutic potential for SCID-X1 and other genetic disorders.
• * The findings open new avenues for gene therapy applications in HSCs.